INSTITUTO DE INVESTIGACIÓN BIOMÉDICA DE SALAMANCA
Instituto
Oregon Health & Science University
Portland, Estados UnidosPublicaciones en colaboración con investigadores/as de Oregon Health & Science University (32)
2024
-
CARE-radiology statement explanation and elaboration: reporting guideline for radiological case reports
BMJ Evidence-Based Medicine
-
Integrating the 40-Gene Expression Profile (40-GEP) Test Improves Metastatic Risk-Stratification Within Clinically Relevant Subgroups of High-Risk Cutaneous Squamous Cell Carcinoma (cSCC) Patients
Dermatology and Therapy, Vol. 14, Núm. 3, pp. 593-612
2023
-
Anakinra for Refractory Cytokine Release Syndrome or Immune Effector Cell-Associated Neurotoxicity Syndrome after Chimeric Antigen Receptor T Cell Therapy
Transplantation and Cellular Therapy, Vol. 29, Núm. 7, pp. 430-437
-
Clinical parameters affecting survival outcomes in patients with low-grade serous ovarian carcinoma: An international multicentre analysis
CMAJ. Canadian Medical Association Journal, Vol. 66, Núm. 3, pp. E310-E320
-
Direct oral anticoagulants in pediatric venous thromboembolism: Experience in specialized pediatric hemostasis centers in the United States
Research and Practice in Thrombosis and Haemostasis, Vol. 7, Núm. 1
-
Ovarian cancer pathology characteristics as predictors of variant pathogenicity in BRCA1 and BRCA2
British Journal of Cancer, Vol. 128, Núm. 12, pp. 2283-2294
2022
2021
-
Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)1
Autophagy, Vol. 17, Núm. 1, pp. 1-382
-
Identification of a locus near ULK1 associated with progression-free survival in ovarian cancer
Cancer Epidemiology Biomarkers and Prevention, Vol. 30, Núm. 9, pp. 1669-1680
-
International harmonization in performing and reporting minimal residual disease assessment in multiple myeloma trials
Leukemia, Vol. 35, Núm. 1, pp. 18-30
-
Therapeutic anticoagulation with heparin in noncritically ill patients with covid-19
New England Journal of Medicine, Vol. 385, Núm. 9, pp. 790-802
2020
-
A multicenter retrospective study of 223 patients with t(14;16) in multiple myeloma
American Journal of Hematology, Vol. 95, Núm. 5, pp. 503-509
-
Daratumumab, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone in Patients With Previously Treated Multiple Myeloma: Three-year Follow-up of CASTOR
Clinical Lymphoma, Myeloma and Leukemia, Vol. 20, Núm. 8, pp. 509-518
-
Different MAF translocations confer similar prognosis in newly diagnosed multiple myeloma patients
Leukemia and Lymphoma, Vol. 61, Núm. 8, pp. 1885-1893
2019
-
Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial
The Lancet, Vol. 394, Núm. 10193, pp. 121-130
-
Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial
The Lancet, Vol. 394, Núm. 10193, pp. 131-138
-
The search for noise-induced cochlear synaptopathy in humans: Mission impossible?
Hearing Research, Vol. 377, pp. 88-103
2018
-
Daratumumab plus bortezomib and dexamethasone versus bortezomib and dexamethasone in relapsed or refractory multiple myeloma: Updated analysis of CASTOR
Haematologica, Vol. 103, Núm. 12, pp. 2079-2087
-
Identification of a novel locus on chromosome 2q13, which predisposes to clinical vertebral fractures independently of bone density
Annals of the rheumatic diseases, Vol. 77, Núm. 3, pp. 378-385
2017
-
Analyses of germline variants associated with ovarian cancer survival identify functional candidates at the 1q22 and 19p12 outcome loci
Oncotarget, Vol. 8, Núm. 39, pp. 64670-64684